The Systems Serology platform

What is Systems Serology?

What is Systems Serology

A suite of functional and biophysical assays developed at the Ragon Institute that enables the collection of population-level functional and biophysical antibody profiles.

  • Robust, high-throughput, rapid, and highly reproducible bead- and plate-based assays linked to system biology/machine learning algorithms.
  • Easily adaptable to analyze antibody responses against any antigen, both known and unknown.
  • Defines the specific characteristics of the most protective humoral immune responses in both monoclonal antibodies and polyclonal pools of antibodies via Fc effector function assays and links function back to biophysical antibody features.
  • Currently run to a GCLP-like standard, meaning that each assay is qualified and reports detailing assay sensitivity, reproducibility and performance are available. SeromYx expects to be GCLP in 2021.

Systems Serology A suite of tools to guide design of better vaccines and therapeutics
Systems Serology: A suite of tools to guide design of better vaccines and therapeutics

What are the steps to a Systems Serology analysis?

  1. Take serum samples from immune, recovered or treated subjects and control subjects, over time (vaccines) or a panel of monoclonal antibodies (mAbs).-
  2. Run the suite of 12 tests that both describe the antibody/innate function and explain that function through biophysical characteristics of the antibody; SeromYx blinded.-
  3. Provide raw data from the tests (hundreds of data points/sample) to client.-
  4. SeromYx unblinded. Run computational algorithm to sort signal from noise in large and disparate dataset and avoid overfitting.-
  5. Share results of the analysis with the client: Actionable insight: What function correlates with efficacy? (Discovery) What construct delivers that function? (Development).

What are the Components of the Assay Suite?

SeromYx’ Systems Serology platform contains a suite of twelve high throughput assays. Nine assays interrogate antibody function and three assays describe antibody biophysical structure and thus link the specified effector function(s) back to the biophysical structure of the Fc region of the antibody. For more information on effector function how the Fc region of antibodies drives it, please click here.

Nine functional assays:

  • ADCP (antibody dependent cellular phagocytosis)
  • ADCC (antibody dependent cellular cytotoxicity)
  • ADNKA (antibody dependent NK cell activation)
  • ADED (antibody dependent eosinophil degranulation)
  • ADBD (antibody dependent basophil degranulation)
  • ADCD (antibody dependent complement deposition)
  • ADNP (antibody dependent neutrophil activation/phagocytosis)
  • ADDCP (antibody dependent dendritic cell phagocytosis)
  • ADMB (antibody dependent mucin binding)

Three biophysical assays:

  • Fc receptor array
  • Antibody glycosylation analysis
  • Antibody subclassing

What are the applications for this versatile technology?

Systems Serology is a versatile platform that provides the tools to link antibody structure with antibody function with clinical outcome. It can be used in both discovery (to identify the correlates of clinical outcome) and development (to guide rational design of vaccines, monoclonals and immunotherapies) For more information and case studies of applications for Systems Serology, click here.

Specifically, Systems Serology can be used for correlates analysis, to identify the mechanistic immune markers associated with natural infection (disease outcome), vaccination or treatment. The technology can also support the analysis of animal studies; we currently have assays to support mouse and NHP studies, but could adapt to other species based on client need.

Downstream of correlates, Systems Serology supports the development of vaccine design strategies (e.g., prime/boost, Dose and timing (e.g., delayed fractional dose), adjuvants) and screening therapeutic monoclonal antibodies for desired function.

Additional use at an earlier stage of application include the use of select assays as clinical trial endpoints, or full suite analysis leading to markers of disease state in infectious disease or in immuno-oncology.

updated: 9 months ago